Adding pelabresib to treatment with ruxolitinib reduced spleen size in patients with JAK inhibitor-naïve myelofibrosis in the phase 3 MANIFEST-2 trial. Adding pelabresib to treatment with ruxolitinib reduced spleen size in patients with JAK inhibitor-naïve myelofibrosis in the phase 3 MANIFEST-2 trial.